In this MEDtalk Peter Schmid present updated data for overall survival from Impassion 130-study – a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer.   This 2nd IMpassion130 interim OS analysis confirming clinically meaningful OS benefit of this treatment ...

Progression-free and overall survival were significantly improved with first line treatment with pertuzumab, trastuzumab, and docetaxel in 808 pts with HER2-positive metastatic breast cancer.  OS was increased by an unprecedented 15.7 month. In this MEDtalk Sandra M. Swain present the end-of-study analysis with a median follow-up of 99 month (max ...

The 2010 Affordable Care Act, ACA, expanded access to insurance and care for many Americans. In this MEdtalks Anna Jo Smith evaluate the impact of the ACA on stage at diagnosis and time to treatment for women with ovarian cancer.  ...

In this MEDtalk Kamal Chamoun explain, why nsurance type and regional income are associated with Multiple Myeloma survival. This may be related to affordability of oral antineoplastic medications. Prices have been rapidly escalating and there are well described issues with affordability.  ...

The Phase III MONALEESA-7 study demonstrated that the addition of ribociclib to a nonsteroidal aromatase inhibitor or tamoxifen + goserelin significantly extended progression-free survival. In this MEDtalk Yen-Shen Lu explain the effect across gene expression ...

Locally advanced or metastatic urothelial cancer remains a lethal disease with limited treatment options for patients who progress on or after platinum and/or checkpoint inhibitor (CPI).   In this MEDtalk Daniel Peter Petrylak present a new streatment of urothelial cancer  Enfortumab vedotin (EV) – an antibody-drugconjugate targeting Nectin-4, which is highly expressed in UC. This study demonstrate the fact, that Enfortumab vedotin have a therapy that can help people who don’t benefit from checkpoint ...

For Niels Kroman, cheflæge i Kræftens Bekæmpelse og professor ved Københvans Universitet, er det vigtigste budskab fra ASCO, den store betydning som tidlig paliation har for kræftpatienter. Fokus på tidlig paliation bedrer patienternes livskvalitet og bedre overlevelsen  ...

In this MEDtalk Michael R. Migden report from a 12-month follow-up study from a primary analysis of cemiplimab, a human monoclonal anti-pd-1, in patients with metastatic cutaneous squamous cell carcinoma.  Objective response rate was 49.2% and median progression-free survival was 18.4 months. According to Michael R. Migden are cemiplimab a paradigm shift in treatment of these group of patients.  ...

In this MEDtalk Daniel Heinrich present which new data about prostate and kidney cancer he finds most interesting.  ...

Selvom der ikke er nogle nye afgørende gennembrud i behandlingen af lungecancer, så er der flere interessante studier for både immunterapi og targeteret behandling, studier, der på sigt vil få indflydelse på den daglige kliniske behandling. Klik og hør overlæge Odd ...

#Seneste udgivelse

Almen praksis

Nr. 9 • oktober 2019
13. årgang
  • Diabetesmedicin
  • Atrieflimren og apopleksi
  • Kighoste
#

Almen praksis

Bo Gerdes

Bo Gerdes
praktiserende læge

Dorte Halkjær

Dorte Halkjær
praktiserende læge

Jens Georg Hansen

Jens Georg Hansen
overlæge, dr.med., speciallæge i almen medicin

  Tina Enevoldsen

Tina Enevoldsen
praktiserende læge